BDRX
BDRX (Biodexa Pharmaceuticals) - My Watchlist Notes
April 2, 2026
Huge volume surge today – still on my radar
What Happened Today
I’ve been watching BDRX for a while, and today it finally delivered a big move I’ve been hoping for after a long downturn. The stock closed at $0.8733, up +42.23% on massive volume of \~120 million shares. It hit a high of $1.35 intraday with very little retracement during the session.
Read the official press release here.
My Take on the Move
This doesn’t feel like a dead-cat bounce. Today’s explosion came with legitimate news, extreme volume, and almost no immediate heavy selling. Zacks just initiated coverage calling it a “deep value oncology platform.”
Key Upcoming Event
1-for-5 Reverse ADR Split effective Monday, April 6, 2026. This is to help regain Nasdaq compliance. These splits often create short-term volatility.
Live Chart on TradingView
Possible Scenarios
- Bullish continuation: If volume stays elevated, we could push toward $1.20–$1.50+ pre-split.
- Profit-taking pullback: Watch for a hold above $0.65–$0.75.
- Split-driven volatility: Nominal price jumps \~5x after April 6. Could spark another leg up or immediate selling.
- Fade: If volume dries up, cash burn and dilution remain the long-term risks.
Potential Entry, Exit Points & Probability Setup
All prices are pre-reverse split (1-for-5 on April 6). Based on today’s close of $0.8733, volume profile, support levels, and the MTX240 catalyst. These are my personal estimates only — subjective and for planning purposes. Biotech micro-caps are extremely volatile.
| Entry Point | Exit Target | % Return | Est. Probability of hitting target |
Scenario / Notes |
|---|---|---|---|---|
|
$0.78 – $0.85 (pullback to key support zone) |
$1.20 | +41% to +54% | \~55% | Bullish continuation if volume stays strong. First realistic upside leg pre-split. |
| $1.45 – $1.55 | +71% to +99% | \~28% | Extended momentum run (high-volume breakout continuation). Less likely but higher reward. | |
|
$0.87 – $0.92 (current momentum / breakout hold) |
$1.05 – $1.10 | +14% to +26% | \~65% | Quick near-term scalp on continued buying pressure. Highest probability setup. |
|
$0.87+ (aggressive at-the-market entry) |
$1.35 (intraday high retest) | +47% | \~40% | Re-test of today’s spike high. Requires sustained volume into the weekend. |
|
Stop Loss (below key support) |
Below $0.68 | -13% to -22% (from entry range) |
\~35% | Invalidation level. Protects capital if support breaks on low volume. |
Notes: Probabilities are my subjective assessment based on similar biotech catalyst moves + today’s volume profile. Not guaranteed. Risk-reward favors the $0.78–$0.85 entry zone (approx. 2:1 to 3:1 on first target). Position size small — this is high-risk.
Risks to Consider
• Extremely volatile micro-cap.
• Limited cash runway (into Q3 2026).
• Low float can reverse fast.
Next Things to Watch
| Date/Event | What I’m Looking For |
|---|---|
| April 3 | Does buying continue or heavy profit-taking? |
| April 6 | Reverse split effective – post-split behavior. |
| April 10 (est.) | Q1 2026 earnings/pipeline updates. |
| Ongoing | MTX240 IND filing & eRapa progress. |
Important Disclaimers
NOT Financial Advice: Personal notes only. BDRX is a high-risk biotech micro-cap. You can lose your entire investment. Do Your Own Research (DYOR). Consult a professional before trading.
Personal observations only. High-risk. Position sizing matters.
Comments
Post a Comment